This entry covers evaluation under DC 6310. A clinician establishes the diagnosis separately.
How is it connected to service?
The applicable direct, secondary, aggravation or presumptive route determines the service-connection evidence. Use the evidence guide to distinguish these routes.
Explore service-connection evidence →What do the rating levels describe?
A diagnosis does not automatically establish a percentage. These are the source requirements for evaluating severity; related notes and exceptions still apply.
Find DC 6310 in the rating schedule
The highlighted row marks this code. Nearby rows provide context and can describe other conditions. Use the full schedule for applicable headings, footnotes and exceptions.
| Rating | |
|---|---|
| Evaluate under the General Rating Formula. | |
| Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, heart damage. | |
| 6310 Syphilis, and other treponema infections: | |
| Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, diseases of the nervous system, vascular system, eyes, or ears (see DC 7004, DC 8013, DC 8014, DC 8015, and DC 9301). | |
| 6311 Tuberculosis, miliary: | |
| As active disease | 100 |
| Inactive disease: See §§ 4.88c and 4.89. | |
| Note 1: Confirm the recurrence of active infection by culture, histopathology, or other diagnostic laboratory testing. | |
| Note 2: Rate under the appropriate body system any residual disability of infection which includes, but is not limited to, skin conditions and conditions of the respiratory, central nervous, musculoskeletal, ocular, gastrointestinal, and genitourinary systems and those residuals listed in § 4.88c. |
Related notes and evaluation rules
Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, diseases of the nervous system, vascular system, eyes, or ears (see DC 7004, DC 8013, DC 8014, DC 8015, and DC 9301).
Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, diseases of the nervous system, vascular system, eyes, or ears (see DC 7004, DC 8013, DC 8014, DC 8015, and DC 9301). |
Which evidence addresses the questions?
- Diagnosis and history: Records identifying the current diagnosis, onset, course, and relevant medical history.
- Diagnostic tests and measurements: Condition-relevant tests, imaging, laboratory results, and objective measurements.
- Symptoms and episodes: Records or statements documenting symptoms, severity, frequency, duration, and episodes.
- Clinical findings: Examination findings that are relevant to the public DBQ or rating criteria.
- Scars and residual findings: Records describing relevant scars and residual physical findings.
- Functional impact: Medical and lay evidence describing work and daily-activity effects.
- Service connection evidence: Evidence addressing an in-service event, exposure, disease, injury, continuity, or a secondary relationship.
Find evidence in the Infectious Diseases (other than HIV-related illness chronic fatigue syndrome and tuberculosis) questionnaire
Use these section names and page numbers to locate the examiner’s findings. Some sections apply only to particular diagnoses within this family.
- diagnosis · p. 1, 2
- medical history · p. 3
- status, symptoms, and residuals · p. 3, 4
- other pertinent physical findings, scars, complications, conditions, signs and/or symptoms · p. 4
- diagnostic testing · p. 5, 6
- functional impact · p. 6
- remarks · p. 7
Shared library and examination references
How an independent medical review works →Sources and scope
Clinical and evidence sources
Guide source check: 2026-11-06. Rating-library snapshot: June 30, 2026. Source coverage is distinct from clinical review. This page does not diagnose, adjudicate a claim, or collect medical records.
Shared reference edition 1.2.4 · source check 2026-11-06. Coverage is stated for each framework and is distinct from clinical review. Rating-source snapshot: 2026-06-30.